Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltest
Final published version, 1.3 MB, PDF document
BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented.
CASE PRESENTATION: We are presenting a patient with metastatic melanoma who developed severe ICI-induced enterocolitis multirefractory for glucocorticoids, infliximab and vedolizumab, partially responding to faecal microbiota transplantation and final complete response to tofacitinib.
CONCLUSION: This case supports that tofacitinib may be an(other) effective agent in managing multirefractory ICI-induced diarrhoea caused by colitis and/or enteritis.
| Original language | English |
|---|---|
| Article number | e000989 |
| Journal | BMJ Open Gastroenterology |
| Volume | 9 |
| Issue number | 1 |
| Number of pages | 4 |
| ISSN | 2054-4774 |
| DOIs | |
| Publication status | Published - 2022 |
Bibliographical note
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
- Humans, Fecal Microbiota Transplantation/adverse effects, Antineoplastic Agents, Immunological/adverse effects, Enterocolitis/chemically induced, Colitis/therapy
Research areas
ID: 333478308